Revvity, Inc., announced the launch of its EONIS Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.
The EONIS Q system simplifies and streamlines molecular testing for SMA and SCID with an innovative workflow, inclusive of the EONIS Q96 instrument, the EONIS SCID-SMA kit and dedicated EONIS EASI software.
Turnaround time for the EONIS Q workflow from sample-in to result is approximately three hours. There are no wash steps required and fewer pipetting and centrifuging steps involved, further reducing hands-on time. Compared to other methods, the EONIS Q system uses fewer consumables and one-time use plasticware.
